Medite Cancer Diagnostics Inc (MDIT)

[BondsSF]

During 2013, a key focus of our management team was to raise the awareness of our product portfolio in the U.S. and increase the amount of revenue we generated from the American market. These efforts have been well-timed as thousands of labs in the U.S. will need to utilize leading products to meet the burgeoning demand resulting from the passage of the Affordable Care Act. By partnering with Medline we position ourselves for even greater growth in 2014 and beyond while at the same time reducing our operating costs," commented Michaela Ott, co-president of MEDITE Group.

"We decided to partner with Medline after a comprehensive review of our competitive position in the U.S. and Canadian markets," added Ott. "We chose Medline because of its strategic focus on the $700 million histology market represented by an aggressive expansion into the segment beginning this year. This market is growing greater than 10 percent annually, so Medline recognized the dynamic growth opportunities and is devoting a significant amount of effort to building a leading histology system and consumables resource to hospitals and other healthcare providers. Medline elected to partner with us because of the breadth and quality of our product portfolio and our combined ability to provide cost effective solutions to the healthcare customer."